VentriPoint Historical Financial Ratios
| VPT Stock | CAD 0.10 0.01 9.09% |
VentriPoint Diagnostics is promptly reporting on over 88 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Price To Sales Ratio of 988, Dividend Yield of 0.0, PTB Ratio of 256 or Days Sales Outstanding of 2.2 K will help investors to properly organize and evaluate VentriPoint Diagnostics financial condition quickly.
VentriPoint |
About VentriPoint Financial Ratios Analysis
VentriPoint DiagnosticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate VentriPoint Diagnostics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on VentriPoint financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across VentriPoint Diagnostics history.
VentriPoint Diagnostics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing VentriPoint Diagnostics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on VentriPoint Diagnostics sales, a figure that is much harder to manipulate than other VentriPoint Diagnostics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Invested Capital
Invested capital represents the total cash investment that shareholders and debt holders have contributed to VentriPoint Diagnostics. There are two different methods for calculating VentriPoint Diagnostics invested capital: operating approach and financing approach. Understanding VentriPoint Diagnostics invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Income Quality
An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.Earnings Yield
The inverse of the price-to-earnings ratio, representing the percentage of each dollar invested in the stock that was earned by the company.Most ratios from VentriPoint Diagnostics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into VentriPoint Diagnostics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VentriPoint Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, VentriPoint Diagnostics' Price To Sales Ratio is fairly stable compared to the past year. PTB Ratio is likely to climb to 256.06 in 2024, whereas Free Cash Flow Yield is likely to drop (0.09) in 2024.
| 2023 | 2024 (projected) | Payables Turnover | 0.007882 | 0.007488 | Days Of Inventory On Hand | 295.08 | 280.33 |
VentriPoint Diagnostics fundamentals Correlations
Click cells to compare fundamentals
VentriPoint Diagnostics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
VentriPoint Diagnostics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 147.8 | 62.57 | 186.2 | 617.87 | 940.63 | 987.66 | |
| Ptb Ratio | (2.05) | (2.86) | 5.72 | 9.25 | 243.87 | 256.06 | |
| Days Sales Outstanding | 486.58 | 304.78 | 1.7K | 2.0K | 2.1K | 2.2K | |
| Book Value Per Share | (0.039) | (0.0315) | 0.0612 | 0.0292 | 0.00121 | 0.001149 | |
| Free Cash Flow Yield | (0.47) | (0.16) | (0.0662) | (0.0982) | (0.0822) | (0.0863) | |
| Operating Cash Flow Per Share | (0.0376) | (0.0148) | (0.0231) | (0.0265) | (0.0243) | (0.0255) | |
| Stock Based Compensation To Revenue | 7.25 | 2.53 | 10.96 | 11.71 | 10.03 | 10.53 | |
| Capex To Depreciation | 0.28 | 0.0685 | 0.0872 | 6.0E-5 | 6.9E-5 | 6.6E-5 | |
| Pb Ratio | (2.05) | (2.86) | 5.72 | 9.25 | 243.87 | 256.06 | |
| Ev To Sales | 146.69 | 76.29 | 209.63 | 548.53 | 922.7 | 968.83 | |
| Free Cash Flow Per Share | (0.0378) | (0.0148) | (0.0232) | (0.0265) | (0.0243) | (0.0255) | |
| Roic | 2.38 | 2.24 | (0.45) | (1.07) | (15.04) | (14.29) | |
| Net Income Per Share | (0.0524) | (0.0248) | (0.0285) | (0.0312) | (0.0311) | (0.0326) | |
| Payables Turnover | 0.0367 | 0.009617 | 0.0494 | 0.0123 | 0.007882 | 0.007488 | |
| Sales General And Administrative To Revenue | 26.0 | 19.94 | 41.27 | 44.95 | 57.11 | 59.96 | |
| Research And Ddevelopement To Revenue | 24.1 | 12.89 | 7.55 | 15.41 | 22.03 | 12.03 | |
| Capex To Revenue | 0.45 | 0.21 | 0.1 | 8.1E-5 | 9.4E-5 | 8.9E-5 | |
| Cash Per Share | 2.17E-4 | 0.007059 | 0.0681 | 0.0332 | 0.008253 | 0.007841 | |
| Pocfratio | (2.13) | (6.09) | (15.14) | (10.18) | (12.16) | (12.77) | |
| Capex To Operating Cash Flow | (0.0127) | (0.008978) | (0.00718) | (0.00342) | (0.001353) | (1.0E-6) | |
| Pfcf Ratio | (2.11) | (6.07) | (15.12) | (10.18) | (12.16) | (12.77) | |
| Days Payables Outstanding | 10.0K | 38.0K | 7.4K | 29.7K | 46.3K | 48.6K | |
| Income Quality | 0.72 | 0.59 | 0.81 | 0.85 | 0.78 | 0.71 | |
| Roe | 1.35 | 0.79 | (0.47) | (1.07) | (25.68) | (24.4) | |
| Ev To Operating Cash Flow | (2.6) | (6.86) | (12.24) | (9.04) | (11.93) | (12.53) | |
| Pe Ratio | (1.53) | (3.62) | (12.27) | (8.64) | (9.5) | (9.97) | |
| Return On Tangible Assets | (10.57) | (2.31) | (0.41) | (0.82) | (2.59) | (2.72) | |
| Ev To Free Cash Flow | (2.58) | (6.84) | (12.23) | (9.04) | (11.93) | (12.53) | |
| Earnings Yield | (0.23) | (0.66) | (0.28) | (0.0815) | (0.12) | (0.11) | |
| Net Debt To E B I T D A | (0.36) | (0.54) | 2.46 | 0.99 | 0.19 | 0.18 | |
| Current Ratio | 0.0919 | 0.39 | 8.75 | 5.36 | 1.17 | 1.11 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for VentriPoint Stock Analysis
When running VentriPoint Diagnostics' price analysis, check to measure VentriPoint Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VentriPoint Diagnostics is operating at the current time. Most of VentriPoint Diagnostics' value examination focuses on studying past and present price action to predict the probability of VentriPoint Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VentriPoint Diagnostics' price. Additionally, you may evaluate how the addition of VentriPoint Diagnostics to your portfolios can decrease your overall portfolio volatility.